Get started
Work

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

Year: 2016
Type: article
Abstract: Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0%-18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0%-8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0-6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.
DOI: 10.1016/j.pvr.2016.07.003
Authors: Daniel C. Beachler, Tim Waterboer, Christine M. Pierce Campbell, Donna J. Ingles, Krystle A. Lang Kuhs, Alan G. Nyitray, Allan Hildesheim, Michael Pawlita, Aimée R. Kreimer, Anna R. Giuliano
Institutions: National Cancer Institute, Division of Cancer Epidemiology and Genetics, German Cancer Research Center, Moffitt Cancer Center, Vanderbilt University, Vanderbilt Health
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: gold
Estimated APC paid: $900
Funders: Merck, Moffitt Cancer Center, Ludwig Institute for Cancer Research, Department of Science and Technology, Ministry of Science and Technology, India, Instituto Mexicano del Seguro Social, Instituto Nacional De Salud Pública, Merck Sharp and Dohme, National Cancer Institute
OpenAlex ID: W2495386199
FWCI: 1.562
Cites: 17
Cited by: 13
Related to: 10